During the past decade, Chung Shan Medical University Hospital conducted 88 clinical trials. In the 10-year time frame, 88 clinical trials started and 27 clinical trials were completed, i.e. on average, 30.7% percent of trials that started reached the finish line to date. In the past 5 years, 41 clinical trials started and 12 clinical trials were completed. i.e. 29.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Chung Shan Medical University Hospital" #1 sponsor was "Chung Shan Medical University" with 22 trials, followed by "Pfizer" with 20 trials sponsored, "Janssen Research & Development, LLC" with 9 trials sponsored, "Eli Lilly and Company" with 8 trials sponsored and "Daiichi Sankyo, Inc." with 8 trials sponsored. Other sponsors include 56 different institutions and companies that sponsored additional 44 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Chung Shan Medical University Hospital" #1 collaborator was "AstraZeneca" with 4 trials as a collaborator, "Dermira, Inc." with 3 trials as a collaborator, "Eli Lilly and Company" with 3 trials as a collaborator, "Gilead Sciences" with 3 trials as a collaborator and "Merck Sharp & Dohme LLC" with 3 trials as a collaborator. Other collaborators include 29 different institutions and companies that were collaborators in the rest 36 trials.

According to Clinical.Site data, the most researched conditions in "Chung Shan Medical University Hospital" are "Carcinoma, Non-Small-Cell Lung" (8 trials), "Atopic Dermatitis" (6 trials), "Ankylosing Spondylitis" (5 trials), "Non-small Cell Lung Cancer" (4 trials) and "Rheumatoid Arthritis" (4 trials). Many other conditions were trialed in "Chung Shan Medical University Hospital" in a lesser frequency.

Most popular intervention types in "Chung Shan Medical University Hospital" are "Drug" (92 trials), "Other" (22 trials), "Biological" (10 trials), "Device" (6 trials) and "Diagnostic Test" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (39 trials), "Carboplatin" (7 trials), "Pemetrexed" (6 trials), "Amivantamab" (5 trials) and "Lazertinib" (5 trials). Other intervention names were less common.

The vast majority of trials in "Chung Shan Medical University Hospital" are 122 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Chung Shan Medical University Hospital". undefined are not yet recruiting, 25 are recruiting, 20 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 60 completed trials in Chung Shan Medical University Hospital, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Chung Shan Medical University Hospital, 6 "Phase 1" clinical trials were conducted, 21 "Phase 2" clinical trials and 58 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 9 trials, and there were also 14 trials that are defined as “Not Applicable".